---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019877"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:26:10.174103+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anebulo Q3 FY2024 net loss $0.06/shr vs $0.11; pivots to pediatric cannabis antidote

## Summary
- Net loss $1.7M ($0.06/shr), narrower than $2.8M ($0.11) a year ago; operating expenses $1.7M (down 41%).
- Cash and equivalents $5.1M as of March 31, 2024, down from prior quarter but no near-term capital raise flagged.
- Prioritizing IV formulation of selonabant for unintentional cannabis poisoning in children, citing growing medical need.
- DEA plans to reclassify marijuana as Schedule III cited as tailwind; FDA discussions support alternative formulation for pediatric use.
- Adult ACI treatment remains market opportunity but pediatric path seen as faster to approval; Phase 2 oral study data already completed.

## SEC filing metadata
- accession: 0001493152-24-019877
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315224019877/0001493152-24-019877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315224019877/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019877
- JSON: https://secwatch.observer/filing/0001493152-24-019877.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019877.txt

## Key facts
- Earnings Releases
  Anebulo Pharmaceuticals, Inc. reported three months ended March 31, 2024 results: net income Net loss ... was $1.7 million, or $(0.06) per share, EPS $(0.06) per share.
  - Period: three months ended March 31, 2024
  - Net income: Net loss ... was $1.7 million, or $(0.06) per share
  - EPS: $(0.06) per share
  - Result: reported results
  source text: today announced financial results for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315224019877/0001493152-24-019877-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.